U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Cancer Policy Forum; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary. Washington (DC): National Academies Press (US); 2015 Dec 9.

Cover of The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research

The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary.

Show details

REFERENCES

  • Baneux PJ, Martin ME, Allen MJ, Hallman TM. Issues related to institutional animal care and use committees and clinical trials using privately owned animals. ILAR Journal. 2014;55(1):200–209. [PubMed: 24936040]
  • Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy. 2014;10(8):1415–1425. [PMC free article: PMC4203518] [PubMed: 24991836]
  • Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study human diseases. Current Opinion in Endocrinology, Diabetes, and Obesity. 2010;17(2):120. [PMC free article: PMC2892284] [PubMed: 20150806]
  • Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Journal of Clinical Oncology. 2005;23(16):3676–3685. [PubMed: 15738535]
  • Chi JT, Thrall DE, Jiang C, Snyder S, Fels D, Landon C, McCall L, Lan L, Hauck M, MacFall JR, Viglianti BL, Dewhirst MW. Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics. Clinical Cancer Research. 2011;17(8):2549–2560. [PMC free article: PMC3078971] [PubMed: 21292819]
  • Couzin-Frankel J. When mice mislead. Science. 2013;324(6161):922–925. [PubMed: 24264972]
  • Dewhirst MW, Winget JM, Edelstein-Keshet L, Sylvester J, Engler M, Thrall DE, Page RL, Oleson JR. Clinical application of thermal isoeffect dose. International Journal of Hyperthermia. 1987;3(4):307–318. [PubMed: 3668312]
  • Dewhirst MW, Phillips TL, Samulski TV, Stauffer P, Shrivastava P, Paliwal B, Pajak T, Gillim M, Sapozink M, Myerson R. RTOG quality assurance guidelines for clinical trials using hyperthermia. International Journal of Radiation Oncology Biology Physics. 1990;18(5):1249–1259. [PubMed: 2347733]
  • DiMasi JA, Grabowski HG. Economics of new oncology drug development. Journal of Clinical Oncology. 2007;25(2):209–216. [PubMed: 17210942]
  • DiMasi JA, Reichert JM, Feldman L, Malins A. Clinical approval success rates for investigational cancer drugs. Clinical Pharmacology & Therapeutics. 2013;94(3):329–335. [PubMed: 23739536]
  • Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of Clinical Oncology. 2006;24(1):25–35. [PubMed: 16314617]
  • Gordon I, Paoloni M, Mazcko C, Khanna C. The Comparative Oncology Trials Consortium: Using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Medicine. 2009;6(10):e1000161. [PMC free article: PMC2753665] [PubMed: 19823573]
  • Grimm D. Dawn of the dog. Science. 2015;348(6232):274–279. [PubMed: 25883337]
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. [PubMed: 10647931]
  • Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646–674. [PubMed: 21376230]
  • Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nature Biotechnology. 2014;32(1):40–51. [PubMed: 24406927]
  • HHS (U.S. Department of Health and Human Services). Introduction to the conduct of responsible research. 2007. [July 16, 2015]. https://ori​.hhs.gov/sites​/default/files/rcrintro.pdf.
  • HHS. § 46.116 Informed consent checklist—Basic and additional elements. 2014a. [July 16, 2015]. www​.hhs.gov/ohrp/policy/consentckls.html.
  • HHS. Informed consent information sheet. 2014b. [July 16, 2015]. www​.fda.gov/downloads​/RegulatoryInformation​/Guidances/UCM405006.pdf.
  • Holden SA, Emi Y, Kakeji Y, Northey D, Teicher BA. Host distribution and response to antihumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants. Cancer Chemotherapy and Pharmacology. 1997;40(1):87–93. [PubMed: 9137536]
  • Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(29):13075–13080. [PMC free article: PMC2919935] [PubMed: 20615965]
  • Khanna C, London C, Vail D, Mazcko C, Hirschfeld S. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clinical Cancer Research. 2009;15(18):5671–5677. [PMC free article: PMC2748812] [PubMed: 19737961]
  • Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M. Toward a drug development path that targets metastatic progression in osteosarcoma. Clinical Cancer Research. 2014;20(16):4200–4209. [PMC free article: PMC4134738] [PubMed: 24803583]
  • Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates. Nature Reviews Drug Discovery. 2004;3(8):711–715. [PubMed: 15286737]
  • Liu J, Blake SJ, Smyth MJ, Teng MW. Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clinical & Translational Immunology. 2014;3(8):e22. [PMC free article: PMC4232074] [PubMed: 25505970]
  • London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research. 2003;9(7):2755–2768. [PubMed: 12855656]
  • London CA, Bear MD, McCleese J, Foley KP, Paalangara R, Inoue T, Ying W, Barsoum J. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS ONE. 2011;6(11):e27018. [PMC free article: PMC3207826] [PubMed: 22073242]
  • London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin JR, McCauley D, Kauffman M, Shacham S. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: Results of a phase 1 study. PLoS ONE. 2014;9(2):e87585. [PMC free article: PMC3913620] [PubMed: 24503695]
  • Lora-Michiels M, Yu D, Sanders L, Poulson JM, Azuma C, Case B, Vujaskovic Z, Thrall DE, Charles HC, Dewhirst MW. Extracellular pH and P-31 magnetic resonance spectroscopic variables are related to outcome in canine soft tissue sarcomas treated with thermoradiotherapy. Clinical Cancer Research. 2006;12(19):5733–5740. [PubMed: 17020978]
  • Marech I, Patruno R, Zizzo N, Gadaleta C, Introna M, Zito AF, Gadaleta CD, Ranieri G. Masitinib (AB1010), from canine tumor model to human clinical development: Where we are. Critical Reviews in Oncology and Hematology. 2014;91(1):98–111. [PubMed: 24405856]
  • McGrath JC, McLachlan EM, Zeller R. Transparency in research involving animals: The Basel Declaration and new principles for reporting research in BJP manuscripts. British Journal of Pharmacology. 2015;172(10):2427–2432. [PMC free article: PMC4409896] [PubMed: 25899710]
  • Mestas J, Hughes CC. Of mice and not men: Differences between mouse and human immunology. The Journal of Immunology. 2004;172(5):2731–2738. [PubMed: 14978070]
  • NCI (National Cancer Institute). NCI guidelines for auditing clincial trials for the NCI National Clinical Trials Network (NCTN) program, Community Clinical Oncology Program (CCOP)/NCI Community Oncology Resarch Program (NCORP) and research bases. 2014. [July 16, 2015]. http://ctep​.cancer.gov​/branches/ctmb/clinicalTrials​/docs/ctmb_audit_guidelines​.pdf.
  • Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer. 2008;8(2):147–156. [PubMed: 18202698]
  • Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK. Launching a novel preclinical infrastructure: Comparative Oncology Trials Consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS ONE. 2009a;4(3):e4972. [PMC free article: PMC2659423] [PubMed: 19330034]
  • Paoloni M, Davis S, Lana S, Withrow D, Sangiorgi L, Picci P, Hewitt S, Triche T, Meltzer P, Khanna C. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics. 2009b;10(1):625. [PMC free article: PMC2803201] [PubMed: 20028558]
  • Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery. 2010;9:203–214. [PubMed: 20168317]
  • Prescott DM, Charles HC, Poulson JM, Page RL, Thrall DE, Vujaskovic Z, Dewhirst MW. The relationship between intracellular and extracellular pH in spontaneous canine tumors. Clinical Cancer Research. 2000;6(6):2501–2505. [PubMed: 10873105]
  • Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA. Proof of target for SU11654: Inhibition of KIT phosphorylation in canine mast cell tumors. Clinical Cancer Research. 2003;9(15):5729–5734. [PubMed: 14654558]
  • Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT, Hwang SK, Jin H, Churchwell MI, Cho MH. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nature Chemical Biology. 2006;2(10):543–550. [PubMed: 16936720]
  • Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014;10(8):1369–1379. [PMC free article: PMC4203514] [PubMed: 24991839]
  • Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, Fridland A, Lee WA, Plunkett W, Vail D, Thamm DH, Jeraj R, Tumas DB. GS-9219—A novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clinical Cancer Research. 2008;14(9):2824–2832. [PubMed: 18451250]
  • Roy S, Bayly CI, Gareau Y, Houtzager VM, Kargman S, Keen SL, Rowland K, Seiden IM, Thornberry NA, Nicholson DW. Maintenance of caspase-3 proenzyme dormancy by an intrinsic “safety catch” regulatory tripeptide. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(11):6132–6137. [PMC free article: PMC33434] [PubMed: 11353841]
  • Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. [PMC free article: PMC2844940] [PubMed: 20332509]
  • Shapiro SG, Raghunath S, Williams C, Motsinger-Reif AA, Cullen JM, Liu T, Albertson D, Ruvolo M, Bergstrom Lucas A, Jin J, Knapp DW, Schiffman JD, Breen M. Canine urothelial carcinoma: Genomically aberrant and comparatively relevant. Chromosome Research. 2015;23(2):311–331. [PMC free article: PMC4501039] [PubMed: 25783786]
  • Simpson RM, Bastian BC, Michael HT, Webster JD, Prasad ML, Conway CM, Prieto VM, Gary JM, Goldschmidt MH, Esplin DG, Smedley RC, Piris A, Meuten DJ, Kiupel M, Lee CC, Ward JM, Dwyer JE, Davis BJ, Anver MR, Molinolo AA, Hoover SB, Rodriguez-Canales J, Hewitt SM. Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell & Melanoma Research. 2014;27(1):37–47. [PMC free article: PMC4066658] [PubMed: 24128326]
  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine. 2001;344(11):783–792. [PubMed: 11248153]
  • Thomas R, Duke SE, Wang HJ, Breen TE, Higgins RJ, Linder KE, Ellis P, Langford CF, Dickinson PJ, Olby NJ, Breen M. “Putting our heads together”: Insights into genomic conservation between human and canine intracranial tumors. Journal of Neuro-Oncology. 2009;94(3):333–349. [PMC free article: PMC3225023] [PubMed: 19333554]
  • Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clinical Cancer Research. 2009;15(10):3503–3510. [PubMed: 19417014]
  • Viglianti BL, Lora-Michiels M, Poulson JM, Lan L, Yu D, Sanders L, Craciunescu O, Vujaskovic Z, Thrall DE, MacFall J, Charles CH, Wong T, Dewhirst MW. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clinical Cancer Research. 2009;15(15):4993–5001. [PMC free article: PMC2763531] [PubMed: 19622579]
  • West DC, Qin Y, Peterson QP, Thomas DL, Palchaudhuri R, Morrison KC, Lucas PW, Palmer AE, Fan TM, Hergenrother PJ. Differential effects of procaspase-3 activating compounds in the induction of cancer cell death. Molecular Pharmacology. 2012;9(5):1425–1434. [PMC free article: PMC3348238] [PubMed: 22486564]
Copyright 2015 by the National Academy of Sciences. All rights reserved.
Bookshelf ID: NBK338440

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.7M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...